Open | 10.41 |
Previous Close | 10.37 |
Day Range | 10.21 - 11.31 |
52-Week Range | 6.11 - 19.00 |
All-Time High | 5,798.42 |
Avg. Volume (50-day) | 185,963.02 |
EPS (TTM) | 0.05 |
Next Earnings Date | 2025-08-11 (BMO) |
Last Earnings Date | 2025-05-09 |
Forward Annual Dividend (Yield) | - |
Trailing Annual Dividend (Yield) | - |
Options | Yes |
P/E Ratio | 216.49 |
PEG Ratio | 1.6 |
Price to Book | 13.34 |
Price to Cash Flow | - |
Price to Free Cash Flow | - |
Total Sales (TTM) | 100.64 M |
Revenue per Share (TTM) | 0.99 |
Shares Outstanding | 88.101 M |
Share Float (%) | 15.88 M |
% Held by Institutions | 2.96 |
Dividends Per Share (TTM) | - |
Ex-Dividend Date | - |
+/- EMA(20) | 10.19 (+10.01%) |
+/- SMA(50) | 9.25 (+21.19%) |
+/- SMA(200) | 11.48 (-2.35%) |
5-Day Perf. | +2.47% |
1-Month Perf. | +29.75% |
3-Month Perf. | -2.86% |
6-Month Perf. | -0.71% |
YTD Perf. | -7.36% |
1-Year Perf. | -17.21% |
RSI(14) | 59.04 |
ATR(14) | 0.85 |
ADX(14) | 27.13 |
Beta (5Y) | 0.94 |
As a StockCharts Member, you can review earnings results and analyze revenue and earnings growth over time. Bring a balance of technicals and fundamentals to your approach when you join today!
Gyre Therapeutics, Inc. operates as a biopharmaceutical company. It is focused on the development and commercialization of Hydronidone (F351) for the treatment of Metabolic Dysfunction Associated Steatohepatitis (MASH-associated liver fibrosis). The firm operates through the BC and Gyre segments. The company was founded on March 7, 1997 and is headquartered in San Diego, CA.
GYRE has triggered the following predefined scans:
Elder Bar Turned Blue |
P&F Double Top Breakout |
As a StockCharts Member, you can create your own unique alerts with the technical criteria that matters most to you. Stay ahead of important moves and never miss a thing in the markets.
As a StockCharts Member, you can save the charts you're watching to your own account with ChartLists. Accessible from any device, you can organize, review and analyze your charts on-the-go, anytime, anywhere.